Substance / Medication

Zidovudine

Overview

Active Ingredient
zidovudine
RxNorm CUI
11413
Labeler: Coupler LLCUpdated: 2026-01-19T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

WARNING: RISK OF HEMATOLOGICAL TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS 5.1 [see Warnings and Precautions ()]. 5.3 [see Warnings and Precautions ()]. 5.4 [see Warnings and Precautions ()]. Zidovudine tablets have been associated with hematologic toxicity including

Contraindications

When this intervention should not be used

Zidovudine tablets are contraindicated in patients who have had a potentially life-threatening hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to any of the components of the formulations.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis.
Shafiee Arman, Seighali Niloofar, Taherzadeh-Ghahfarokhi Nooshin et al. · Virol J · 2023
PMID: 37287047Meta-AnalysisFull text (PMC)
Zidovudine use in pregnancy and congenital malformations.
Rough Kathryn, Sun Jenny W, Seage George R et al. · AIDS · 2017
PMID: 28537936Meta-AnalysisFull text (PMC)
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey Muki S, Kongnyuy Eugene J, Alobwede Samuel M et al. · Cochrane Database Syst Rev · 2013
PMID: 23543540Meta-AnalysisFull text (PMC)
Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding Alicen, Rutherford George W, Siegfried Nandi · Cochrane Database Syst Rev · 2010
PMID: 20687097Meta-Analysis
Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
Bazarbachi Ali, Plumelle Yves, Carlos Ramos Juan et al. · J Clin Oncol · 2010
PMID: 20585095Meta-Analysis
A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
Shey Muki, Kongnyuy Eugene J, Shang Judith et al. · Cochrane Database Syst Rev · 2009
PMID: 19588374Meta-Analysis
Zidovudine: a targeted therapy for endemic Burkitt's lymphoma.
Kurokawa M, Andela V, Ghosh S et al. · East Afr Med J · 2005
PMID: 16619691Meta-Analysis
Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults.
Darbyshire J, Foulkes M, Peto R et al. · Cochrane Database Syst Rev · 2000
PMID: 10796852Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Zidovudine (substance)
SNOMED CT
387151007
UMLS CUI
C0043474
RxNorm CUI
11413
Labeler
Coupler LLC

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.